133 related articles for article (PubMed ID: 22528598)
21. Diabetes and rehab.
Slovik DM
Rehab Manag; 1997; 10(2):46-8, 52-3, 116. PubMed ID: 10165951
[No Abstract] [Full Text] [Related]
22. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
23. Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topyildiz F; Kiyici S; Gul Z; Sigirli D; Guclu M; Kisakol G; Cavun S
J Diabetes Res; 2016; 2016():1309502. PubMed ID: 26998491
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
25. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
Colwell JA
Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
[No Abstract] [Full Text] [Related]
26. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
27. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.
Blaslov K; Zibar K; Bulum T; Duvnjak L
Clin Res Hepatol Gastroenterol; 2014 Jun; 38(3):e61-3. PubMed ID: 24315013
[No Abstract] [Full Text] [Related]
28. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Cvetković RS; Plosker GL
Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
[TBL] [Abstract][Full Text] [Related]
29. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
[No Abstract] [Full Text] [Related]
30. DCCT: implications for diabetes care in the UK.
Boulton AJ
Diabet Med; 1993 Oct; 10(8):687. PubMed ID: 8261748
[No Abstract] [Full Text] [Related]
31. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents.
Donaghue KC; Wadwa RP; Dimeglio LA; Wong TY; Chiarelli F; Marcovecchio ML; Salem M; Raza J; Hofman PL; Craig ME;
Pediatr Diabetes; 2014 Sep; 15 Suppl 20():257-69. PubMed ID: 25182318
[No Abstract] [Full Text] [Related]
32. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
Painter NA; Morello CM; Singh RF; McBane SE
J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
[TBL] [Abstract][Full Text] [Related]
33. [Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study].
Gaede PH; Jepsen PV; Parving HH; Pedersen OB
Ugeskr Laeger; 1999 Jul; 161(30):4277-85. PubMed ID: 10439688
[TBL] [Abstract][Full Text] [Related]
34. Single-visit screening of diabetic complications.
McGill MJ; Yue DK; Plehwe WE; Willey KA; Turtle JR
Diabetes Care; 1989 Sep; 12(8):599-600. PubMed ID: 2776593
[No Abstract] [Full Text] [Related]
35. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
Fitchett D
Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
[No Abstract] [Full Text] [Related]
36. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
37. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
[TBL] [Abstract][Full Text] [Related]
38. Workshop VIII--Retinopathy, nephropathy, neuropathy, and tight control.
Lebovitz HE; Vinik AI
Am J Med; 1991 Feb; 90(2A):80S-84S. PubMed ID: 1994725
[No Abstract] [Full Text] [Related]
39. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
40. [Evidence based therapy with insulin in diabetic patients].
Jermendy G
Orv Hetil; 2005 Feb; 146(8):341-52. PubMed ID: 15803885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
